



US009408859B2

(12) **United States Patent**
Skulachev et al.

(10) **Patent No.:** US 9,408,859 B2
(45) **Date of Patent:** *Aug. 9, 2016

(54) **PHARMACEUTICAL COMPOSITIONS
USEFUL FOR PREVENTING AND TREATING
CANCER**

(71) Applicant: **Mitotech SA**, Luxembourg (LU)

(72) Inventors: **Vladimir P. Skulachev**, Moscow (RU);
Maxim V. Skulachev, Moscow (RU)

(73) Assignee: **MITOTECH S.A.**, Luxembourg (LU)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/674,443**

(22) Filed: **Nov. 12, 2012**

(65) **Prior Publication Data**

US 2013/0072463 A1 Mar. 21, 2013

Related U.S. Application Data

(63) Continuation-in-part of application No. 12/524,961, filed as application No. PCT/RU2007/000044 on Jan. 29, 2007, now Pat. No. 8,349,902.

(51) **Int. Cl.**

A61K 31/66 (2006.01)
A61K 31/4745 (2006.01)
A61K 31/352 (2006.01)
A61K 31/4355 (2006.01)
A61K 31/473 (2006.01)
A61K 31/4741 (2006.01)

(52) **U.S. Cl.**

CPC *A61K 31/66* (2013.01); *A61K 31/352* (2013.01); *A61K 31/4355* (2013.01); *A61K 31/473* (2013.01); *A61K 31/4741* (2013.01); *A61K 31/4745* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,538,974 A	7/1996	Ogawa et al.
6,331,532 B1	12/2001	Murphy et al.
7,109,189 B2	9/2006	Murphy et al.
2002/0044913 A1	4/2002	Hamilton
2007/0270381 A1	11/2007	Murphy et al.
2008/0275005 A1	11/2008	Murphy et al.

FOREIGN PATENT DOCUMENTS

EP	1047701 B1	5/2005
EP	1534720 A1	6/2005
EP	1321138 B1	4/2006
RU	2318500 C2	3/2008
WO	99/26582 A2	6/1999
WO	2004/014927 A1	2/2004
WO	2006/005759 A2	1/2006

WO	2007/046729 A1	4/2007
WO	2008/048134 A1	4/2008
WO	2009/005386 A1	1/2009
WO	WO 2011108946 A1 *	9/2011

OTHER PUBLICATIONS

Bakeeva et al. Biochemistry (Moscow), 2008, vol. 73, No. 12, pp. 1288-1299.*

Agapova, et al. (2008) "Mitochondria-Targeted Plastoquinone Derivatives as Tools to Interrupt Execution of the Aging Program. 3. Inhibitory Effect of SkQ1 on Tumor Development From p53-Deficient Cells," Biochem. (Mosc.), 73(12):1300-1316 (+ 3 fig. pages). Antonenko, et al. (2008) "Mitochondria-Targeted Plastoquinone Derivatives as Tools to Interrupt Execution of the Aging Program. 1. Cationic Plastoquinone Derivatives: Synthesis and In Vitro Studies," Biochem. (Mosc.), 73(12):1273-1287 (+ 1 fig. page).

Dugina, et al. (2009) " β - and γ -Cytoplasmic Actins Display Distinct Distribution and Functional Diversity," J. Cell Sci., 122(16):2980-2988.

Fernández-Medarde, et al. (2011) "Ras in Cancer and Developmental Diseases," Genes & Canc., 2(3):344-358.

Havens, et al. (2006) "Regulation of Late G1/S Phase Transition and APCCdh1 by Reactive Oxygen Species," Mol. Cell. Biol., 26(12):4701-4711.

Popova, et al., (2010) "Scavenging of Reactive Oxygen Species in Mitochondria Induces Myofibroblast Differentiation," Antiox. & Redox. Signal., 13(9):1297-1307.

Pylayeva-Gupta, et al. (2011) "RAS Oncogenes: Weaving a Tumorigenic Web," Nature Reviews/Canc., 11:761-774.

Sundaresan, et al. (1995) "Requirement for Generation of H2O2 for Platelet-Derived Growth Factor Signal Transduction," Science, 270:296-299.

Adlam et al. (2005) "Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury," FASEB J., 19:1088-1095.

Anisimov (2007) "Molecular and Physiological Mechanisms of Aging," Antioksidanty, Nov. 27, 2007, [on line] http://imquest.alfaspace.net/Book/MFMA/mfma_3_9_2.htm?embedded=yes translated from Russian to English.

Antonenko et al. (2008) "Protective effects of mitochondria-targeted antioxidant SkQ in aqueous and lipid membrane environments," J. Membr. Biol., 222:141-149.

Becker (2004) "New concepts in reactive oxygen species and cardiovascular reperfusion physiology" Cardiovascular Research, 61:461-470.

(Continued)

Primary Examiner — Jeffrey S Lundgren

Assistant Examiner — Stephanie Springer

(74) *Attorney, Agent, or Firm* — Wayne A. Keown; Verrill Dana LLP

(57) **ABSTRACT**

Disclosed is a method of treating a cancer on a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of a compound

